Published • loading... • Updated
Alx Oncology outlines interim ASPEN-09 data from ~80 patients by mid-2027 as CD47-high cohort shows 22-month median PFS (NASDAQ:ALXO)
Summary by Seeking Alpha
1 Articles
1 Articles
Alx Oncology outlines interim ASPEN-09 data from ~80 patients by mid-2027 as CD47-high cohort shows 22-month median PFS (NASDAQ:ALXO)
ALX Oncology (ALXO) Q1 2026 earnings call: CD47-high HER2+ breast cancer shows durable responses with evorpacept; key 2026–2027 readouts.
·United States
Read Full ArticleCoverage Details
Total News Sources1
Leaning Left0Leaning Right1Center0Last UpdatedBias Distribution100% Right
Bias Distribution
- 100% of the sources lean Right
100% Right
R 100%
Factuality
To view factuality data please Upgrade to Premium
